Equities Analysts Offer Predictions for Repligen Q3 Earnings

Key Points

• Leerink Partners raised their Q3 2025 EPS estimate for Repligen to $0.43, up from $0.39, while the current full-year earnings estimate is $1.72 per share.
• Repligen reported Q2 earnings of $0.37 per share, missing estimates, but showed a 14.8% increase in quarterly revenue year-over-year.
• The stock has received a mix of ratings from analysts, with a consensus of "Moderate Buy" and a target price of $170.75.

Repligen Corporation (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of Repligen in a report released on Tuesday, July 29th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings of $0.43 per share for the quarter, up from their previous estimate of $0.39. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.71 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.63 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. Repligen's revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business earned $0.40 EPS.

Other equities research analysts have also recently issued research reports about the company. Evercore ISI cut their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada raised their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research note on Wednesday. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Finally, Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average target price of $169.45.

Repligen Trading Up 1.6%

RGEN stock traded up $1.84 during midday trading on Thursday, hitting $118.91. 941,488 shares of the company's stock were exchanged, compared to its average volume of 948,438. The business has a 50-day simple moving average of $123.39 and a two-hundred day simple moving average of $136.49. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $6.68 billion, a PE ratio of -475.62, a P/E/G ratio of 2.15 and a beta of 1.05. Repligen has a 1-year low of $102.96 and a 1-year high of $182.52.

Institutional Trading of Repligen

Several hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its holdings in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after buying an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after buying an additional 594,189 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Repligen in the fourth quarter valued at $53,428,000. Raymond James Financial Inc. purchased a new position in Repligen in the fourth quarter valued at $52,492,000. Finally, Nuveen LLC purchased a new position in Repligen in the first quarter valued at $35,536,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.